HighVista Strategies’s Alexion Pharmaceuticals ALXN Stock Holding History

HighVista Strategies’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-21,530	Closed	-$3.96M	–	153
2021 Q2	$3.96M	Hold	21,530	–	–	2.8%	6
2021 Q1	$3.29M	Buy	+21,530	New	+$3.33M	2.45%	8

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

HighVista Strategies's ALXN Position: Q3 2021 in Review

HighVista Strategies sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 21,530 shares — an estimated $3.96M sold.

HighVista Strategies first reported a position in ALXN in Q1 2021 and held it in 2 quarters. The position peaked at $3.96M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

HighVista Strategies reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
HighVista Strategies sold 21,530 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3.96M.
HighVista Strategies first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 2 quarters.
HighVista Strategies's Alexion Pharmaceuticals position peaked at $3.96M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on HighVista Strategies's 13F filing for Q3 2021, filed 15 Nov 2021.